Ezetimibe
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Ezetimibe and local guidelines before prescribing.
Cholesterol absorption inhibitor
Mechanism
Inhibits intestinal cholesterol absorption (NPC1L1).
Uses
Primary hypercholesterolaemia (add-on to statin or statin-intolerant).
Dosing
- If the target is not met: Add ezetimibe 10 mg daily, then consider other NICE-approved options (e.g. inclisiran, PCSK9 inhibitors).
Cardiology: Ischaemic Heart Disease (ACS) › 1.31 Secondary Prevention - Ezetimibe | 10 mg daily when further LDL lowering is needed.
Cardiology: Ischaemic Heart Disease (ACS) › 1.33 Drug Reference Table - Ezetimibe 10 mg daily: Blocks gut cholesterol absorption and lowers LDL by about 20% more. The first add-on (NICE TA385).
Endocrinology: Lipids and obesity - Ezetimibe | 10 mg daily. First add-on when targets are not met.
Endocrinology: Lipids and obesity
2 more dose entries from the chapters
- High-intensity statin (e.g. atorvastatin 20–80 mg) aiming for at least a 50% LDL reduction; add ezetimibe .
Clinical Genetics: Cancer genetics and inherited cardiovascular conditions - Secondary prevention: atorvastatin 80 mg (lower dose if interactions or CKD); lipid-lowering targets LDL ≤2.0 mmol/L or non-HDL ≤2.6 mmol/L; add ezetimibe, then inclisiran or a PCSK9 inhibitor if criteria are met.
General Practice: Long-term conditions, multimorbidity and polypharmacy
Side effects
Diarrhoea, abdominal pain, myalgia, raised liver enzymes.
Interactions
Ciclosporin raises levels; fibrates and cholestyramine alter absorption.
Contraindications and cautions
Active liver disease with statin
Monitoring
Lipids, LFT with statin
Pregnancy and breastfeeding
Avoid
Renal and hepatic impairment
Avoid in moderate to severe liver impairment
Overdose and reversal
Supportive
Special advice
Check LFT with a statin; modest LDL lowering.
More from the textbook: uses, cautions and other points
- Ezetimibe - blocks intestinal cholesterol absorption (NPC1L1); added to statins or used if statins aren't tolerated.
Cardiology: Anatomy Physiology and Pharmacology - Ezetimibe / inclisiran / PCSK9 inhibitors | Additional LDL lowering.
Cardiology: Anatomy Physiology and Pharmacology - Bempedoic acid with ezetimibe (NICE TA694): When statins are contraindicated or not tolerated, and ezetimibe alone is not enough.
Endocrinology: Lipids and obesity - True intolerance of all statins is uncommon. If it occurs, use ezetimibe, bempedoic acid or inclisiran.
Endocrinology: Lipids and obesity - Normal or mildly raised CK - consider a break and re-challenge, a lower dose, or a different statin. Don't abandon lipid lowering - consider ezetimibe, bempedoic acid or inclisiran.
Neurology: Neuromuscular disease - FH | LDLR, APOB, PCSK9 | High-intensity statin + ezetimibe; cascade testing
Clinical Genetics: Cancer genetics and inherited cardiovascular conditions
Where it is discussed in the book
- Cardiology: Anatomy Physiology and Pharmacology (2 mentions)
- Cardiology: Ischaemic Heart Disease (ACS) (2 mentions)
- Endocrinology: Lipids and obesity (8 mentions)
- Neurology: Neuromuscular disease (1 mention)
- Clinical Genetics: Cancer genetics and inherited cardiovascular conditions (4 mentions)
- Integrated cardiology chapter (2 mentions)
- General Practice: Long-term conditions, multimorbidity and polypharmacy (1 mention)
- Biochemistry: Metabolism of carbohydrates, lipids and proteins (1 mention)